KKR buys Capsugel from Pfizer

Published: 2-Aug-2011
Finance

Pays US$2.4bn in cash


New York-based private equity group Kohlberg Kravis Roberts (KKR) has bought Pfizer’s Capsugel business for US$2.4bn, following approval by the US and EU regulatory authorities.

Capsugel is the world’s leading provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries.

The firm offers a range of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to innovative r&d equipment and liquid formulations as part of its Licaps drug delivery system.

Capsugel generated about $750m in revenue last year.

The firm will maintain a corporate presence in the US, with its global headquarters located in New Jersey. All Pfizer employees currently dedicated to this business will be transferred to Capsugel, which will be led Guido Driesen.

Pfizer will announce its second quarter results later today (2 August).

  • Companies:
  • Pfizer
See more

You may also like

Manufacturing

Pfizer licenses 3SBio's oncology bispecific antibody, SSGJ-707 for up to $4.8bn

Read more
The bispecific antibody has demonstrated initial efficacy in patients with non-small cell lung metastatic colorectal cancer, as well as gynaecological tumours

Trending Articles

  1. Almac expands bioavailability capabilities to address a critical need in drug development Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
  2. Fidia Farmaceutici enters the UK market with the acquisition of Altacor Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group
  3. Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
  4. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland
  5. Quintiles invests a further US$14m in China Will also expand lab testing capabilities with SCRC

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Pfizer licenses 3SBio's oncology bispecific antibody, SSGJ-707 for up to $4.8bn

The bispecific antibody has demonstrated initial efficacy in patients with non-small cell lung metastatic colorectal cancer, as well as gynaecological tumours
Drug Delivery

Pfizer enters into merger with Seagen

The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfilment of customary closing conditions
Research & Development

Touchlight and Pfizer to use dbDNA to manufacture mRNA-based vaccines, therapeutics and gene therapies

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies
Manufacturing

Biovac to manufacture Pfizer-BioNTech vaccine for African Union

Pfizer and BioNTech expect the Cape Town facility to be incorporated into the vaccine supply chain by the end of 2021
Finance

Report details relative uptake of COVID-19 vaccines in EU

$746 m worth of the vaccines have been distributed in the EU with Pfizer taking 67% market share
Research & Development

Pfizer partners with Medicines Manufacturing Innovation Centre

The company will be participating in the centre’s first ‘grand challenge,’ aiming to develop a continuous direct compression platform for oral solid dosage medicines
Regulatory

4D pharma, Merck and Pfizer trial combination carcinoma treatment

MRx0518 is currently being evaluated in three clinical trials in patients with cancer
Subscribe now